Last updated: September 7, 2026
Tafenoquine succinate is a niche antimalarial marketed in the United States as Arakoda for malaria prevention and Krintafel for prevention of relapse in Plasmodium vivax malaria. The product has regulatory differentiation but limited commercial scale. Its value depends on military procurement, travel medicine, malaria-control programs, and specialist prescribing rather than broad retail demand.
The U.S. commercial rights are associated with 60 Degrees Pharmaceuticals for Arakoda. Krintafel was developed and commercialized by GlaxoSmithKline. Public disclosures do not provide a consolidated, independently reported global revenue series for tafenoquine succinate. The available evidence supports a small-market, high-concentration commercial profile rather than a mass-market pharmaceutical franchise.
What is tafenoquine succinate used for?
Tafenoquine succinate is the succinate salt of tafenoquine, an 8-aminoquinoline antimalarial. It has two principal uses:
| Product |
Active ingredient |
FDA indication |
FDA approval |
| Arakoda |
Tafenoquine succinate |
Prophylaxis of malaria in adults |
2018 |
| Krintafel |
Tafenoquine succinate |
Radical cure and prevention of relapse of P. vivax malaria in patients at least 16 years old receiving appropriate antimalarial therapy |
2018 |
Arakoda is administered as a weekly malaria-prevention regimen after a loading schedule. Krintafel is administered as a single dose with chloroquine or another appropriate blood-stage antimalarial, subject to the product label.
Tafenoquine and primaquine can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase deficiency. Quantitative G6PD testing is required before treatment. Tafenoquine is contraindicated in patients with G6PD deficiency or unknown G6PD status under the U.S. labels.[1,2]
How large is the tafenoquine succinate market?
The addressable market is structurally narrow.
Malaria prophylaxis market
Arakoda competes in malaria prevention against:
- Atovaquone/proguanil, including Malarone and generic versions
- Doxycycline
- Mefloquine
- Primaquine
- Tafenoquine
Tafenoquine’s weekly dosing can reduce adherence burden compared with daily products. Its commercial disadvantage is the G6PD testing requirement and the narrower familiarity of prescribers and travelers.
The largest U.S. customer groups are:
- Military and government agencies
- International travelers
- Occupational groups with repeated malaria exposure
- Specialty travel clinics
- Aid and public-health programs
The military market is strategically important because procurement can generate concentrated orders, but it is also volatile. A single contract or formulary change can materially affect a small commercial company’s revenue.
P. vivax relapse-prevention market
Krintafel addresses a clinical problem that is poorly served by conventional blood-stage antimalarials. P. vivax forms dormant liver-stage parasites that can reactivate after initial treatment. Tafenoquine offers a single-dose radical-cure option, while primaquine generally requires a longer course.
The commercial opportunity is greater in endemic regions than in the United States, but access depends on local approvals, G6PD testing capacity, public-health procurement, and malaria-program funding. These conditions limit near-term private-sector revenue.
What is the financial trajectory of tafenoquine succinate?
Tafenoquine succinate does not have the revenue profile of a conventional primary-care or specialty blockbuster. Its financial trajectory is best characterized as a low-base, contract-sensitive commercialization story.
Commercial ownership and revenue concentration
GlaxoSmithKline developed tafenoquine with Medicines for Malaria Venture and retained the Krintafel U.S. launch. 60 Degrees Pharmaceuticals acquired rights associated with Arakoda and has focused on commercialization in the United States.[3,4]
The relevant financial characteristics are:
| Factor |
Commercial effect |
| Small patient population |
Limits prescription volume |
| Weekly prophylaxis dosing |
Supports differentiation |
| G6PD testing requirement |
Creates a prescribing and access barrier |
| Government and military demand |
Can produce large but irregular orders |
| No broad chronic-use indication |
Limits recurring prescription revenue |
| Specialist distribution |
Raises customer-acquisition costs |
| Limited competitor education |
Requires targeted medical marketing |
| Public-health use case |
Expands potential volume but pressures pricing |
60 Degrees Pharmaceuticals’ public filings describe Arakoda as its principal commercial product and identify dependence on product sales, financing, and government or institutional opportunities.[4] The filings do not establish a separately audited global revenue stream for all tafenoquine succinate products. Krintafel sales have not been reported as a material standalone segment by GSK.
Financial trajectory by phase
| Period |
Market event |
Financial implication |
| 2018 |
FDA approvals for Arakoda and Krintafel |
Created two approved U.S. commercial pathways |
| 2019-2021 |
Early commercialization |
Demand constrained by limited awareness and travel disruption |
| 2020-2021 |
COVID-19 travel collapse |
Reduced travel-medicine demand |
| 2022 onward |
Travel recovery and commercial expansion |
Improved prophylaxis opportunity |
| 2023 onward |
Public-market financing by 60 Degrees |
Increased funding capacity but also raised execution and dilution risk |
| Current trajectory |
Niche commercialization |
Revenue remains dependent on contracts, specialist uptake, and procurement |
The pandemic disproportionately affected Arakoda because travel-related malaria prophylaxis declined sharply. Recovery in international travel improved the market but did not convert tafenoquine into a high-volume product.
When does tafenoquine succinate lose exclusivity?
Tafenoquine succinate is a small-molecule drug, so the primary competitive threat is generic substitution rather than biosimilar competition.
U.S. regulatory exclusivity for the 2018 approvals has expired. The products therefore rely primarily on patent rights, labeling differentiation, manufacturing know-how, regulatory complexity, and commercial execution.
The FDA granted Krintafel priority review and approval under a public-health framework. Arakoda also received approval for malaria prophylaxis in adults. Regulatory exclusivity periods associated with those approvals do not create a long-term barrier comparable to an active composition-of-matter patent.[1,2]
Exact patent expiry analysis depends on the specific U.S. patent claims, terminal disclaimers, patent-term adjustment, Orange Book listing, and whether a patent covers the approved product or only a formulation or method of use. Public product labeling alone does not establish the full patent estate.
What patents protect tafenoquine succinate?
The relevant patent categories are:
Composition and salt patents
Earlier patent families may cover tafenoquine, related 8-aminoquinoline compounds, pharmaceutical salts, or crystalline forms. The commercial importance of a tafenoquine succinate salt patent depends on:
- Claim scope
- Filing and priority dates
- Patent-term adjustment
- Terminal disclaimers
- Enablement and written-description support
- Whether the claim covers the marketed salt
- Whether the patent is listed in the FDA Orange Book
Formulation patents
Formulation protection may cover tablets, excipients, stability, dissolution, or dosage strength. Such patents generally provide weaker protection than a valid composition-of-matter patent because a generic applicant may design around the formulation claims.
The U.S. products use oral tablets. No biologic manufacturing barrier applies.
Method-of-use patents
Method-of-use claims may cover:
- Malaria prophylaxis
- Radical cure of P. vivax
- Relapse prevention
- Dosing schedules
- Use in defined patient populations
Method-of-use claims can support litigation against a generic applicant that seeks an indication containing the patented use. Their practical value depends on the approved label, the scope of the patent claims, physician prescribing behavior, and the ability to enforce induced-infringement theories.
What is the Orange Book status of Arakoda and Krintafel?
Arakoda and Krintafel are FDA-approved prescription drugs. Their regulatory status is distinct from the question of whether a generic product has been approved.
A complete Orange Book assessment requires current FDA listing data for:
- NDA number
- Reference-listed-drug status
- Listed patents
- Patent-use codes
- Pediatric exclusivity
- Generic approvals
- Therapeutic-equivalence codes
The FDA labels establish the approved products and indications, but they do not provide a complete current patent-clearance conclusion.[1,2] A generic applicant could pursue an abbreviated new drug application if it can satisfy the applicable bioequivalence, labeling, manufacturing, and patent-certification requirements.
Which companies are challenging tafenoquine succinate?
No major public Paragraph IV litigation campaign against Arakoda or Krintafel is established in the cited FDA labels or the principal public company materials. The absence of a disclosed challenge does not eliminate generic risk. It indicates that the market may not yet support the development cost, regulatory work, and commercial launch expense associated with a dedicated tafenoquine product.
Potential challengers would likely include:
- Generic oral-antimalarial manufacturers
- Contract development and manufacturing organizations
- Public-health suppliers
- Regional manufacturers in malaria-endemic countries
The commercial case for a generic is strongest where government procurement creates predictable volume. The case is weaker in the U.S. retail market, where annual demand is limited and G6PD testing constrains prescribing.
What generic launch risks exist?
A generic launch would face several technical and commercial barriers:
- Bioequivalence for the approved tablet formulation
- Demonstration of adequate product stability
- G6PD-related labeling requirements
- Limited prescriber familiarity
- Small and concentrated demand
- Potential patent claims covering formulation or use
- Procurement qualification requirements
- Need for reliable active-ingredient supply
A generic applicant could enter through a narrow label that omits a patented method of use, depending on the Orange Book patent-use code and applicable regulatory pathway. That strategy would reduce patent exposure but could also reduce the commercial addressable market.
Is biosimilar risk relevant to tafenoquine succinate?
No. Tafenoquine succinate is a chemically synthesized small molecule, not a biologic. Biosimilar legislation and biologic interchangeability rules do not apply.
The relevant competitive risks are:
- Abbreviated new drug applications
- Authorized generics
- Off-label use of primaquine
- Lower-cost antimalarial regimens
- Regional copies outside the United States
- Government tenders that prioritize price
How does tafenoquine compare with primaquine and atovaquone/proguanil?
| Attribute |
Tafenoquine |
Primaquine |
Atovaquone/proguanil |
| Main differentiation |
Weekly prophylaxis; single-dose radical cure |
Established radical cure option |
Broad travel-prophylaxis use |
| G6PD testing |
Required |
Required |
Not generally required |
| Dosing burden |
Lower for selected regimens |
Higher for radical cure |
Daily |
| Market familiarity |
Lower |
Higher in endemic care |
High among travelers |
| Generic competition |
Emerging risk |
Extensive |
Extensive |
| Commercial position |
Niche, differentiated |
Low-cost standard |
Large established market |
Tafenoquine’s strongest commercial argument is convenience. Its main weakness is operational complexity around G6PD testing and limited clinical familiarity.
What licensing deals affect tafenoquine succinate?
The program was developed through collaboration involving GSK and Medicines for Malaria Venture. The U.S. Arakoda commercialization strategy later became associated with 60 Degrees Pharmaceuticals.[3,4]
These arrangements divide value across:
- Original research and development
- Regulatory approvals
- Commercial rights
- Public-health access
- Manufacturing and supply
- Geographic licensing
The principal business risk is that the drug’s public-health value may exceed its commercial return. Malaria products often require partnerships, grants, government procurement, or milestone-based licensing to reach endemic-market patients.
What patent litigation affects tafenoquine succinate?
The cited public materials do not establish a material ongoing U.S. patent-litigation campaign involving Arakoda or Krintafel. Litigation risk remains dependent on the current patent register, future ANDA filings, Paragraph IV certifications, and the specific claims asserted.
The most likely dispute areas are:
- Tafenoquine succinate composition claims
- Tablet formulation claims
- Dosing and radical-cure methods
- Label carve-outs
- Induced infringement
- Patent-term calculations
What geographic markets matter most?
The United States is the clearest regulated commercial market because both Arakoda and Krintafel have FDA approval. Australia and other malaria-exposed markets may offer additional opportunities, but each market requires separate regulatory, pricing, and procurement analysis.
Commercial expansion into endemic countries depends on:
- National treatment guidelines
- WHO policy alignment
- G6PD testing availability
- Drug registration
- Public-health budgets
- Local manufacturing or import requirements
- Tender pricing
The global opportunity is larger than U.S. sales, but it is less predictable and more dependent on institutions than on private prescriptions.
Key Takeaways
- Tafenoquine succinate has two FDA-approved U.S. products: Arakoda and Krintafel.
- The market is niche and concentrated in military, travel, specialist, and public-health channels.
- Public disclosures do not establish a large standalone revenue stream for tafenoquine succinate.
- Arakoda’s financial performance is exposed to travel volume, government contracts, and commercial execution.
- Krintafel addresses an important P. vivax relapse-prevention need but faces access and G6PD-testing constraints.
- Tafenoquine is a small molecule, so generic risk is more relevant than biosimilar risk.
- FDA approval exclusivity has expired; remaining protection depends on active patents, Orange Book listings, and enforceable formulation or method-of-use claims.
- No major public Paragraph IV litigation campaign is established in the cited sources.
- The strongest long-term commercial route is institutional procurement and malaria-program adoption rather than broad retail prescribing.
FAQs
Is tafenoquine succinate the same as tafenoquine?
Tafenoquine is the active pharmaceutical ingredient. Tafenoquine succinate is the salt form used in the marketed oral products.
Is Arakoda available as a generic?
A generic version may be legally possible, but generic availability depends on FDA approval, patent certifications, manufacturing economics, and commercial demand. Product approval alone does not confirm that a generic has launched.
Does tafenoquine succinate require G6PD testing?
Yes. Quantitative G6PD testing is required before use because tafenoquine can cause severe hemolysis in deficient patients.
Which company owns Arakoda?
60 Degrees Pharmaceuticals is associated with the U.S. commercialization of Arakoda. GSK developed tafenoquine and commercialized Krintafel in the United States.
Is tafenoquine succinate a high-revenue pharmaceutical product?
No public evidence supports classification as a high-revenue product. Its commercial profile is a specialized, low-volume franchise with potential upside from military, travel, and public-health procurement.
References
-
U.S. Food and Drug Administration. (2018). Arakoda (tafenoquine succinate) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2018). Krintafel (tafenoquine succinate) prescribing information. FDA.
-
Medicines for Malaria Venture. (n.d.). Tafenoquine. Medicines for Malaria Venture.
-
60 Degrees Pharmaceuticals, Inc. (2023). Annual report and registration statements. U.S. Securities and Exchange Commission.
